Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD

36.01  -1.16 (-3.12%)

After market: 36.01 0 (0%)

Fundamental Rating

4

Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 572 industry peers in the Biotechnology industry. While JANX has a great health rating, there are worries on its profitability. While showing a medium growth rate, JANX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year JANX has reported negative net income.
JANX had a negative operating cash flow in the past year.
JANX had negative earnings in each of the past 5 years.
In the past 5 years JANX always reported negative operating cash flow.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

JANX has a Return On Assets of -8.71%. This is amongst the best in the industry. JANX outperforms 87.74% of its industry peers.
JANX has a Return On Equity of -9.23%. This is amongst the best in the industry. JANX outperforms 90.41% of its industry peers.
Industry RankSector Rank
ROA -8.71%
ROE -9.23%
ROIC N/A
ROA(3y)-13.75%
ROA(5y)-130.91%
ROE(3y)-15.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -1K -2K

1.3 Margins

JANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JANX has been increased compared to 1 year ago.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 32.31 indicates that JANX is not in any danger for bankruptcy at the moment.
The Altman-Z score of JANX (32.31) is better than 96.27% of its industry peers.
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.31
ROIC/WACCN/A
WACC9.44%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

JANX has a Current Ratio of 38.80. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
JANX has a Current ratio of 38.80. This is amongst the best in the industry. JANX outperforms 99.11% of its industry peers.
JANX has a Quick Ratio of 38.80. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
JANX has a Quick ratio of 38.80. This is amongst the best in the industry. JANX outperforms 99.11% of its industry peers.
Industry RankSector Rank
Current Ratio 38.8
Quick Ratio 38.8
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

JANX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.95%, which is quite impressive.
JANX shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.88%.
EPS 1Y (TTM)20.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
Revenue 1Y (TTM)53.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.56%

3.2 Future

Based on estimates for the next years, JANX will show a very negative growth in Earnings Per Share. The EPS will decrease by -18.89% on average per year.
Based on estimates for the next years, JANX will show a very strong growth in Revenue. The Revenue will grow by 69.04% on average per year.
EPS Next Y-3.78%
EPS Next 2Y-24%
EPS Next 3Y-25.57%
EPS Next 5Y-18.89%
Revenue Next Year74.13%
Revenue Next 2Y-30.75%
Revenue Next 3Y11.81%
Revenue Next 5Y69.04%

3.3 Evolution

JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year JANX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -25.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24%
EPS Next 3Y-25.57%

More info and screens

0

5. Dividend

5.1 Amount

JANX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (2/21/2025, 8:00:02 PM)

After market: 36.01 0 (0%)

36.01

-1.16 (-3.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-07 2025-03-07/amc
Inst Owners113.14%
Inst Owner Change-95.4%
Ins Owners1.83%
Ins Owner Change-15.94%
Market Cap2.08B
Analysts86
Price Target91.55 (154.23%)
Short Float %15.59%
Short Ratio6.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.53%
Min EPS beat(2)-52.65%
Max EPS beat(2)65.71%
EPS beat(4)3
Avg EPS beat(4)15.47%
Min EPS beat(4)-52.65%
Max EPS beat(4)65.71%
EPS beat(8)7
Avg EPS beat(8)20.98%
EPS beat(12)9
Avg EPS beat(12)15.71%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)481.4%
Min Revenue beat(2)-73.78%
Max Revenue beat(2)1036.58%
Revenue beat(4)3
Avg Revenue beat(4)312.49%
Min Revenue beat(4)-73.78%
Max Revenue beat(4)1036.58%
Revenue beat(8)7
Avg Revenue beat(8)238.95%
Revenue beat(12)11
Avg Revenue beat(12)215.15%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.05%
PT rev (3m)32.96%
EPS NQ rev (1m)-6.01%
EPS NQ rev (3m)-15%
EPS NY rev (1m)-1.47%
EPS NY rev (3m)-13.4%
Revenue NQ rev (1m)66.34%
Revenue NQ rev (3m)-69.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 159.12
P/FCF N/A
P/OCF N/A
P/B 3.16
P/tB 3.16
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0.23
BVpS11.38
TBVpS11.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.71%
ROE -9.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.75%
ROA(5y)-130.91%
ROE(3y)-15.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.7%
Cap/Sales 6.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 38.8
Quick Ratio 38.8
Altman-Z 32.31
F-Score5
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)735.98%
Cap/Depr(5y)441.59%
Cap/Sales(3y)46.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-104%
EPS Next Y-3.78%
EPS Next 2Y-24%
EPS Next 3Y-25.57%
EPS Next 5Y-18.89%
Revenue 1Y (TTM)53.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-82.56%
Revenue Next Year74.13%
Revenue Next 2Y-30.75%
Revenue Next 3Y11.81%
Revenue Next 5Y69.04%
EBIT growth 1Y-14.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.73%
EBIT Next 3Y-24.45%
EBIT Next 5YN/A
FCF growth 1Y19.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A